Revenue Concentration Risk

Risk factors remain concentrated: current revenues rely entirely on Kimmtrak, and the company lacks collaboration agreements for its pipeline candidates. Execution risks increase as the firm enters larger, more competitive markets. Potential catalysts for 2026 include second‑half cutaneous melanoma data for Brenetafusp, further Kimmtrak adoption in additional countries, and development milestones across ImmTAX programs.